ReCode: merging RNA therapies and organ-specific delivery for respiratory diseases

ReCode Therapeutics launched on Thursday with an OrbiMed- and Colt Ventures-led $80 million series A round to pair RNA therapeutics for rare respiratory diseases with an organ-specific lipid nanoparticle delivery technology.

The company was formed through a merger between the original ReCode Therapeutics and TranscripTx Inc. earlier this month. MPM Capital, Vida Ventures, Hunt Technology Ventures and Osage University Partners also participated in the oversubscribed round...